Enterovirus Infections  >>  ARC-520  >>  Phase 2
Welcome,         Profile    Billing    Logout  

6 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
ARC-520 / Arrowhead
NCT02349126: Study of ARC-520 in Patient With Chronic Hepatitis B Virus

Withdrawn
2
0
RoW
ARC-520 Injection, ARC-520
Arrowhead Pharmaceuticals
Chronic Hepatitis B
12/15
03/16
NCT02452528: Study of ARC-520 in Participants With Hepatitis B Virus e Antigen (HBeAg) Positive Chronic Hepatitis B Virus

Terminated
2
4
US
ARC-520, Placebo, Entecavir, Baraclude, Tenofovir, Viread, diphenhydramine
Arrowhead Pharmaceuticals
Chronic Hepatitis B
12/16
12/16
NCT02604212 / 2014-004751-31: A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Positive, Chronic Hepatitis B Virus Infection

Terminated
2
32
Europe, RoW
ARC-520, Placebo, entecavir, antihistamine, tenofovir
Arrowhead Pharmaceuticals
Hepatitis B
12/16
12/16
Monarch, NCT02577029 / 2015-005499-46: Study of ARC-520 With or Without Other Drugs Used in the Treatment of Chronic Chronic Hepatitis B Virus (HBV)

Terminated
2
79
Europe, RoW
ARC-520, entecavir, Baraclude, pegylated interferon alpha 2a, Peginterferon, Pegasys, tenofovir disoproxil, Viread, antihistamine
Arrowhead Pharmaceuticals
Hepatitis B, Hepatitis D
12/16
12/16
NCT02738008 / 2014-004201-33: Extension Study of the Safety and Efficacy of Multi-dose Intravenous ARC-520 in Patients With Chronic Hepatitis B (HBV) Infection

Terminated
2
12
Europe, RoW
ARC-520 Injection, entecavir, tenofovir, antihistamine
Arrowhead Pharmaceuticals
Hepatitis B
12/16
12/16
NCT02604199 / 2014-004145-27: A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Negative, Chronic Hepatitis B Virus (HBV) Infection

Terminated
2
58
Europe, RoW
ARC-520 Injection, placebo, entecavir, tenofovir, antihistamine
Arrowhead Pharmaceuticals
Hepatitis B
01/17
01/17

Download Options